贝那普利联合厄贝沙坦治疗射血分数保留心力衰竭的临床观察被引量：2

Clinical observation of combining benazepril with Irbesartan in patients of heart failure with preserved ejection fraction

下载PDF

导出

摘要目的:探讨贝那普利联合厄贝沙坦治疗射血分数保留的心力衰竭(HF-PEF)患者的临床治疗效果。方法:将179例HF-PEF患者随机分配至两组,治疗组(n=92例)给予贝那普利与厄贝沙坦联合治疗;对照组(n=87例)给予贝那普利单用治疗,两组均进行6个月的治疗,比较两组患者6 min步行试验(6MWT),心脏舒张功能超声多普勒指标:E/A比值、左室侧壁E峰减速时间(DT)、E/E'比值,以及N末端前脑钠肽(NT-pro BNP)的变化。结果:联合治疗与贝那普利单用相比,6MWT距离增加,E/A、E/E'、DT改善,NT-pro BNP降低均显著(P<0.05)。结论:贝那普利和厄贝沙坦联合治疗HF-PEF患者可产生更有益的疗效。 Objective To assess the efficacy of benazepril combined with Irbesartan in patients of heart failure with preserved ejection fraction. Method 179 patients of HF- PEF were randomly assigned to treatment group（ n = 92,treated with benazepril plus irbesartan） and control group（ n = 87,treated with benazepril only）. After 6 month,the changes were compared between the two group,including six- minute walk test,diastolic function indices evaluated by ultrasonic cardiogram（ E / A,E / E＇and DT）,as well as plasma level of NT- pro BNP and blood biochemical. Results Compared with the regimen of benazepril only,the regimenof benazepril plus Irbesartan had better effects on the following indices： increase of distance in six- minute walk test,improvement of diastolic function indices evaluated by ultrasonic cardiogram（ E / A,E / E＇ and DT）,reduction of plasma level of NT proB-NP（ P〈0. 05）. Conclusion For patients of HF- PEF the regimen of benazepril plus Irbesartan is superior to that of benazepril alone in most indices observed.

作者何远志陈坚华郑维聪江春燕李喜

机构地区广东省肇庆市广宁县中医院

出处《吉林医学》 CAS 2016年第10期2485-2487,共3页 Jilin Medical Journal

关键词贝那普利厄贝沙坦射血分数保留的心力衰竭 Benazepril Irbesartan Heart failure with preserved ejection fraction

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献10

1Mc Murray JJ,Adamopoulos S,Anker SD,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2012,33(14):1787.
2STEINBERG B A,ZHAO X,HEIDENREICH P A,et al.Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction:prevalence,therapies,and outcomes[J].Circulation,2012,126(1):65.
3KITZMAN D W.Outcomes in patients with heart failure with preserved ejection fraction:it is more than the heart[J].J Am Coll Cardiol,2012,59(11):1006.
4中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量：4664
5BORLAUG B A,LAM C S,ROGER V L,et al.Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction[J].J Am Coll Cardiol,2009,54(5):410.
6张吉平,刘锟,王敏.改善心室重构的药物和方法研究进展[J].中国医药导报,2009,6(26):5-5. 被引量：2
7CLELAND J G,TENDERA M,ADAMUS J,et al.The perindopril in elderly people with chronic heart failure(PEP-CHF)study[J].Eur Heart J,2006,27(19):2338.
8YUSUF S,PFEFFER M A,SWEDBERG K,et al.Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection:the CHARM-Preserved Trial[J].Lancet,2003,362(9386):777.
9SCHILLACI G,PUCCI G,PIRRO M.Pirro,Irbesartan for heart failure with preserved ejection fraction[J].N Engl J Med,2009,360(12):1258.
10贺博,刘永铭.左室射血分数保留心力衰竭的研究进展[J].中国医药指南,2013,11(23):444-445. 被引量：10

二级参考文献19

1Udelson JE.Ventricular remodeling in heart failure and the effect of beta-blockade[J].Am J Cardio,2004,93(9A):43B-48B.
2Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertropnic cardiomyopathy[J].Circulation,2001,104(3):317-324.
3Kaftan HA,Evrengul H,Tanriverdi H,et al.Effect of insulin resistance on left ventrieular structural changes in hypertensive patients[J]. Int Heart,2006, 47(3):391-400.
4Rousseau MF,GurneO,Duprez D,et al.Beneficial neurohormonal profile of spironolactone in severe congestive heart failure:results from the RALES neurohormonal substudy[J]. J Am Coll Cardio,2002,40(9):1596-1601.
5Lariviere R,Lelel M.Endothelin-1 in chronic renal failure and hypertension[J].Can J Pharmaco,2003,81(6):607-621.
6Goddard J, Johnston NR, Hand MF,et al. Endothelin-A receptor antago- nism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure:a comparison of selective and corn bined endothelin receptor blockade[J].Circulation,2004,109(9):1186-1193.
7Allan A, Fenning A,Levick S,et al.Reversal of cardiac dysfunction by selective ET-A receptor antagonism[J]. Br J Pharmaco,2005,146(6):846--853.
8Kirchengast M,Luz M.Endothelin receptor antagonists: clinical realities and future directions[J]. J Cardiovasc Pharmaco,2005,45(2):182-191.
9McMurray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure2012of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J].Eur J Heart Fail,2012,14(8):803-869.
10Owan TE,Hodge DO,Herges RM,et al.Trends in prevalence and outcome of heart failure with preserved ejection fraction[J].N Engl J Med,2006,355(3):251-259.